236 related articles for article (PubMed ID: 27998720)
1. Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment.
Huang CF; Huang CY; Yeh ML; Wang SC; Chen KY; Ko YM; Lin CC; Tsai YS; Tsai PC; Lin ZY; Chen SC; Dai CY; Huang JF; Chuang WL; Yu ML
EBioMedicine; 2017 Feb; 15():81-89. PubMed ID: 27998720
[TBL] [Abstract][Full Text] [Related]
2. Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication.
Huang CF; Wang SC; Yeh ML; Huang CI; Tsai PC; Lin ZY; Chen SC; Dai CY; Huang JF; Chuang WL; Chen A; Yu ML
J Gastroenterol Hepatol; 2019 Jan; 34(1):249-255. PubMed ID: 29932235
[TBL] [Abstract][Full Text] [Related]
3. Association Between MICA Gene Variants and the Risk of Hepatitis C Virus-Induced Hepatocellular Cancer in a Sicilian Population Sample.
Augello G; Balasus D; Fusilli C; Mazza T; Emma MR; Giannitrapani L; Agliastro R; Cervello M; Montalto G
OMICS; 2018 Apr; 22(4):274-282. PubMed ID: 29584564
[TBL] [Abstract][Full Text] [Related]
4. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
Huang CF; Yeh ML; Tsai PC; Hsieh MH; Yang HL; Hsieh MY; Yang JF; Lin ZY; Chen SC; Wang LY; Dai CY; Huang JF; Chuang WL; Yu ML
J Hepatol; 2014 Jul; 61(1):67-74. PubMed ID: 24613362
[TBL] [Abstract][Full Text] [Related]
5. Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma.
Kumar V; Yi Lo PH; Sawai H; Kato N; Takahashi A; Deng Z; Urabe Y; Mbarek H; Tokunaga K; Tanaka Y; Sugiyama M; Mizokami M; Muroyama R; Tateishi R; Omata M; Koike K; Tanikawa C; Kamatani N; Kubo M; Nakamura Y; Matsuda K
PLoS One; 2012; 7(9):e44743. PubMed ID: 23024757
[TBL] [Abstract][Full Text] [Related]
6. Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C.
Huang CF; Huang CI; Yeh ML; Wang SC; Chen KY; Ko YM; Lin CC; Tsai YS; Tsai PC; Lin ZY; Chen SC; Dai CY; Huang JF; Chuang WL; Yu ML
Oncotarget; 2017 May; 8(20):32618-32625. PubMed ID: 28427234
[TBL] [Abstract][Full Text] [Related]
7. The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients.
Huang JF; Yeh ML; Yu ML; Dai CY; Huang CF; Huang CI; Tsai PC; Lin PC; Chen YL; Chang WT; Hou NJ; Lin ZY; Chen SC; Chuang WL
J Gastroenterol Hepatol; 2015 Dec; 30(12):1768-74. PubMed ID: 26094738
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
9. Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response.
Sasaki R; Yamasaki K; Abiru S; Komori A; Nagaoka S; Saeki A; Hashimoto S; Bekki S; Kugiyama Y; Kuno A; Korenaga M; Togayachi A; Ocho M; Mizokami M; Narimatsu H; Ichikawa T; Nakao K; Yatsuhashi H
PLoS One; 2015; 10(6):e0129053. PubMed ID: 26070204
[TBL] [Abstract][Full Text] [Related]
10. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
[TBL] [Abstract][Full Text] [Related]
11. Association between MICA rs2596542 Polymorphism with the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients.
Marangon CG; de Bitencorte JT; Michita RT; Lunge VR; Dos Santos DC; Álvares-da-Silva MR; Simon D
Pathol Oncol Res; 2020 Jul; 26(3):1519-1525. PubMed ID: 31471884
[TBL] [Abstract][Full Text] [Related]
12. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance.
Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ
Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934
[TBL] [Abstract][Full Text] [Related]
13. Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma.
Lange CM; Bibert S; Dufour JF; Cellerai C; Cerny A; Heim MH; Kaiser L; Malinverni R; Müllhaupt B; Negro F; Semela D; Moradpour D; Kutalik Z; Bochud PY;
J Hepatol; 2013 Sep; 59(3):504-9. PubMed ID: 23665287
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation at -1878 (rs2596542) in MICA gene region is associated with chronic hepatitis B virus infection in Saudi Arabian patients.
Al-Qahtani AA; Al-Anazi M; Abdo AA; Sanai FM; Al-Hamoudi W; Alswat KA; Al-Ashgar HI; Khalaf N; Viswan N; Al-Ahdal MN
Exp Mol Pathol; 2013 Dec; 95(3):255-8. PubMed ID: 23994040
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma.
Hai H; Tamori A; Thuy LTT; Yoshida K; Hagihara A; Kawamura E; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N
Sci Rep; 2017 Sep; 7(1):11912. PubMed ID: 28928439
[TBL] [Abstract][Full Text] [Related]
16. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.
Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T
Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the rs2596542 polymorphism in the MICA gene promoter and HBV/HCV infection-induced hepatocellular carcinoma: a meta-analysis.
Luo X; Wang Y; Shen A; Deng H; Ye M
BMC Med Genet; 2019 Aug; 20(1):142. PubMed ID: 31419949
[TBL] [Abstract][Full Text] [Related]
18. Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk.
Lo PH; Urabe Y; Kumar V; Tanikawa C; Koike K; Kato N; Miki D; Chayama K; Kubo M; Nakamura Y; Matsuda K
PLoS One; 2013; 8(4):e61279. PubMed ID: 23593449
[TBL] [Abstract][Full Text] [Related]
19. Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients.
Lee MH; Huang CF; Lai HC; Lin CY; Dai CY; Liu CJ; Wang JH; Huang JF; Su WP; Yang HC; Kee KM; Yeh ML; Chuang PH; Hsu SJ; Huang CI; Kao JT; Chen CC; Chen SH; Jeng WJ; Yang HI; Yuan Y; Lu SN; Sheen IS; Liu CH; Peng CY; Kao JH; Yu ML; Chuang WL; Chen CJ
Sci Rep; 2017 Jun; 7(1):3718. PubMed ID: 28623331
[TBL] [Abstract][Full Text] [Related]
20. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
Ioannou GN; Green PK; Beste LA; Mun EJ; Kerr KF; Berry K
J Hepatol; 2018 Nov; 69(5):1088-1098. PubMed ID: 30138686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
